February 21, 2023 Novo sows the seeds for a new heart failure approach The company reckons it can succeed where other cell therapies have failed, but proof is a long way off.
August 08, 2019 Bluerock unlikely to smooth Bayer’s rocky road Bayer has responded to its current woes by going all in on cell therapy – a move that, even if successful, will take a long time to pay off.
